Next Article in Journal
Identification of Tight-Binding Plasmepsin II and Falcipain 2 Inhibitors in Aqueous Extracts of Marine Invertebrates by the Combination of Enzymatic and Interaction-Based Assays
Next Article in Special Issue
Chemistry and Selective Tumor Cell Growth Inhibitory Activity of Polyketides from the South China Sea Sponge Plakortis sp.
Previous Article in Journal
New Cytotoxic Secondary Metabolites from Marine Bryozoan Cryptosula pallasiana
Previous Article in Special Issue
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessFeature PaperArticle
Mar. Drugs 2017, 15(4), 121; doi:10.3390/md15040121

Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata

1
Department of Nanoengineering, University of California, San Diego, La Jolla, CA 92093, USA
2
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093, USA
3
Department of Biological Sciences, Florida International University, Miami, FL 33199, USA
4
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Yu-Dong Zhou and Dale G. Nagle
Received: 25 February 2017 / Revised: 2 April 2017 / Accepted: 6 April 2017 / Published: 14 April 2017
(This article belongs to the Special Issue Marine Drugs as Antitumour Agents 2017)
View Full-Text   |   Download PDF [1817 KB, uploaded 14 April 2017]   |  

Abstract

A bioactivity guided study of a cf. Caldora penicillata species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1) was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell lung cancer cells in vitro. View Full-Text
Keywords: laucysteinamide A; cyanobacteria; blue-green alga; thiazoline alkaloid; cytotoxicity laucysteinamide A; cyanobacteria; blue-green alga; thiazoline alkaloid; cytotoxicity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zhang, C.; Naman, C.B.; Engene, N.; Gerwick, W.H. Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata. Mar. Drugs 2017, 15, 121.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top